30 closest matches · ranked by relevance
Breast Cancer
Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Breast Neoplasms
Primary: Clinical Benefit Rate (CR Plus PR Plus SD) — 0; 0; 3; 1 participants
Neoplasms
Primary: Progression-free Survival (PFS) - Phase II Part — 7.3; 5.6 Months — p=0.9057
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Postmenopause
Primary: Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7 — 0.028; -0.011…
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Breast Cancer
Primary: Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and…
Estrogen Levels Among Breast Cancer Patients
Primary: Changes in Serum Estradiol — 3.9 pg/mL
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Oestrogen Receptor Positive Advanced Breast Cancer
Primary: Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer — 39…
Breast Cancer · Metastasis
Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants
Perimenopause-Related Depression
Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor-negative Breast Cancer · Progesterone Receptor-positive Breast Cancer
Primary: Best Overall Response — 5; 2 patients with progressive disease
ER+ and AR+ Breast Cancer
Primary: Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects — 16; 15 participants
Breast Cancer
Primary: Mean Percent Positive Proximity Ligation Assays of All Tumor Protein p53-wild Type Breast Tumors in Participants by Treatment Arm — 27.0; 4.4 percentage of positive PLA
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Breast Neoplasms · Breast Cancer · Estrogen-receptor Positive Breast Cancer
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Breast Cancer
Primary: Increase of ER Protein Expression in ER-Negative/Low Breast Cancer — 1 participants
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Breast Cancer
Primary: 2-Year Treatment Discontinuation Rate — 31 percentage of participants — p=0.0011
Breast Cancer · Breast Cancer, Early-Onset
Primary: Change in Proliferative Index (Ki67 Expression) — -14.5; -10.0 Difference from baseline (%) — p=0.002
Estrogen Receptor Positive · HER2/Neu Negative · Male Breast Carcinoma
Primary: Percent Change in Net Influx Constant (Ki) by FLT PET — -32.0 % change — p=0.51
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Post Menopausal Breast Cancer
Primary: Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades — 4; 0; 4; 195 Participants
Breast Cancer
Primary: Clinical Benefit Rate of the Combination of Enzalutamide/ Fulvestrant — 7 Participants
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants